LD-38

• Description :

  LD-38 is a drug-linker conjugate for ADC. LD-38 consists of a topoisomerase 1 inhibitor (Exatecan) (HY-13631) and a highly hydrophilic stable and cleavable linker. LD-38 can be used for synthesis of ADC[1][2].

• UNSPSC :

  12352005

• Target :

  Drug-Linker Conjugates for ADC; Topoisomerase

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCC(N[C@@H](C(C)C)C(N[C@@H](C(NC2=CC=C(COC(N[C@H]3CCC(C(C)=C(F)C=C4N=C5C6=CC7=C8COC([C@](CC)7O)=O)=C4C3=C5CN6C8=O)=O)C=C2)=O)CCC(NCC[N+](C)(CCCS([O-])(=O)=O)C)=O)=O)=O)=O

• Molecular Formula :

  C67H87FN10O20S

• Molecular Weight :

  1403.53

• References & Citations :

  [1]Wu G, et al. KA-3123-LD38: a novel bispecific antibody-drug conjugate (ADC) targeting EGFR and B7H3 with a DNA topoisomerase I inhibitor payload[J]. Cancer Research, 2025, 85 (8_Supplement_1) : 2132-2132.|[2]Catherine C, et al. An anti_itga2 antibody drug conjugate. WO2025153055A1. 2025-07-24.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• Isoform :

  Topo I

• CAS Number :

  [3094583-35-1]